Pulmonx (LUNG) Expected to Announce Quarterly Earnings on Wednesday

Pulmonx (NASDAQ:LUNG) is expected to issue its Q1 2026 results after the market closes on Wednesday, April 29th. Analysts expect Pulmonx to post earnings of ($0.33) per share and revenue of $20.4310 million for the quarter. Interested persons may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Wednesday, April 29, 2026 at 4:30 PM ET.

Pulmonx (NASDAQ:LUNG) last announced its quarterly earnings data on Wednesday, March 4th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.14. Pulmonx had a negative return on equity of 82.79% and a negative net margin of 59.67%.The firm had revenue of $22.60 million for the quarter, compared to analysts’ expectations of $21.73 million. On average, analysts expect Pulmonx to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Pulmonx Stock Performance

NASDAQ LUNG opened at $1.27 on Monday. The firm has a market cap of $53.64 million, a PE ratio of -0.95 and a beta of 0.19. Pulmonx has a 1-year low of $1.13 and a 1-year high of $5.46. The stock has a 50-day moving average of $1.46 and a 200-day moving average of $1.72. The company has a current ratio of 5.07, a quick ratio of 4.28 and a debt-to-equity ratio of 0.68.

Insider Buying and Selling

In other Pulmonx news, CEO Glendon E. French III sold 67,813 shares of the stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $1.43, for a total value of $96,972.59. Following the completion of the sale, the chief executive officer owned 1,409,511 shares in the company, valued at approximately $2,015,600.73. This trade represents a 4.59% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Over the last three months, insiders sold 98,265 shares of company stock worth $140,519. Corporate insiders own 6.80% of the company’s stock.

Hedge Funds Weigh In On Pulmonx

A number of hedge funds and other institutional investors have recently made changes to their positions in LUNG. XTX Topco Ltd bought a new stake in Pulmonx in the second quarter valued at $149,000. Norges Bank bought a new position in Pulmonx in the 2nd quarter worth $392,000. Jane Street Group LLC lifted its position in shares of Pulmonx by 3,328.7% in the 2nd quarter. Jane Street Group LLC now owns 88,631 shares of the company’s stock worth $230,000 after purchasing an additional 86,046 shares during the period. Bank of America Corp DE lifted its position in shares of Pulmonx by 556.6% in the 2nd quarter. Bank of America Corp DE now owns 481,268 shares of the company’s stock worth $1,246,000 after purchasing an additional 407,971 shares during the period. Finally, Two Sigma Investments LP boosted its stake in shares of Pulmonx by 50.3% during the 3rd quarter. Two Sigma Investments LP now owns 46,456 shares of the company’s stock valued at $75,000 after purchasing an additional 15,557 shares in the last quarter. Institutional investors own 91.04% of the company’s stock.

Analysts Set New Price Targets

Several analysts have weighed in on LUNG shares. Canaccord Genuity Group lowered their price objective on Pulmonx from $6.00 to $5.00 and set a “buy” rating for the company in a research report on Thursday, March 5th. Weiss Ratings restated a “sell (e+)” rating on shares of Pulmonx in a report on Thursday, January 22nd. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $14.00 target price on shares of Pulmonx in a research note on Thursday, March 5th. Four equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Pulmonx presently has an average rating of “Hold” and a consensus target price of $5.38.

Pulmonx Company Profile

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.